Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Eur Urol. 2016 Nov 23;72(3):448–454. doi: 10.1016/j.eururo.2016.11.017

Table 4 –

Results of final regression models for reclassification

Base model Area under the curve (95% confidence interval)
4K + clinical model PSA + clinical model Difference
Full clinical model
Initial biopsy 0.783 (0.691–0.871) 0.740 (0.652–0.828) 0.043 (0.003–0.086)
Subsequent biopsy 0.754 (0.657–0.838) 0.755 (0.653–0.841) −0.001 (−0.037–0.041)
Clinical model without prostate volume
Initial biopsy 0.748 (0.654–0.840) 0.678 (0.579–0.774) 0.069 (0.016–0.114)
Subsequent biopsy 0.738 (0.633–0.825) 0.718 (0.611–0.810) 0.02 (−0.023–0.07)

PSA = prostate-specific antigen.

Confidence intervals were calculated with bootstrap accounting for correlations among individuals.